Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citarinostat + Nivolumab in NSCLC
NCT02635061Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2016
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of citarinostat in non-small cell lung cancer (NSCLC), sponsored by Celgene Corporation. Primary endpoints: Number of participants with treatment-related adverse events at 2 years and Recommended Phase 2 Dose at 2 years. Started Aug 2016; status: terminated.
02
Drugs
citarinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02635061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635061.